Abraham Scaria
Seminars
Wednesday 3rd December 2025
Navigating Safety, Efficacy & Delivery for Ocular Gene Therapies to Treat Complement-Mediated Retinal Diseases
11:00 am
- Exploring the critical need to prioritize complement targets with established clinical safety and efficacy profiles to mitigate the risks associated with sustained, irreversible therapeutic action
- Focussing on the complexities of achieving sufficient and consistent protein expression levels from gene therapy vectors to match the complement inhibition level seen with traditional biologics, particularly when targeting the immune-privileged organs like the eye
- Highlighting advancements and ongoing programs and explore how understanding complement biology can inform the design of more effective and targeted gene therapies
Wednesday 3rd December 2025
Panel Discussion: Discussing the Next-Generation of Novel Modalities to be Used for Enhanced Delivery & Broader Impact in CNS & Ophthalmic Indications
12:00 pm
- Addressing the critical challenge of achieving sufficient complement inhibitor exposure in the CNS, a major reason for past failures with peripherally acting drugs
- Exploring novel delivery modalities like gene therapy, shuttle technologies that are in early development, to unlock the therapeutic potential of complement inhibition neurodegenerative diseases
- Highlighting the significant appeal and ongoing development of gene therapies for chronic ophthalmic conditions driven by complement
Wednesday 3rd December 2025
Navigating Safety, Efficacy & Delivery for Ocular Gene Therapies to Treat Complement-Mediated Retinal Diseases
11:00 am
- Exploring the critical need to prioritize complement targets with established clinical safety and efficacy profiles to mitigate the risks associated with sustained, irreversible therapeutic action
- Focussing on the complexities of achieving sufficient and consistent protein expression levels from gene therapy vectors to match the complement inhibition level seen with traditional biologics, particularly when targeting the immune-privileged organs like the eye
- Highlighting advancements and ongoing programs and explore how understanding complement biology can inform the design of more effective and targeted gene therapies
